Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3071 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Boston Scientific acquires CryoCor

Under the terms of the transaction, all remaining outstanding CryoCor shares are entitled to receive $1.35 per share in cash, for a total of approximately $17.6 million. CryoCor

BiPar initiates Phase II uterine cancer study

The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company’s DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.

Big pharma backs changes to Sunshine Act

The Sunshine Act requires drug and device manufacturers to disclose to the Secretary of Health and Human Services (HHS), on a quarterly basis, anything of value given to

Isis to receive $4.6 million from Alnylam

In addition, Isis has the potential to receive portions of future milestone and royalty payments. According to the company, this transaction further emphasizes the value of Isis’s innovation

FDA accepts Watson’s NDA for bladder drug

Watson is seeking marketing approval of this novel transdermal gel of oxybutynin hydrochloride for the treatment of overactive bladder (OAB). Oxybutynin chloride topical gel (OTG) is a clear,